Survodutide
What does "Dual GLP-1/Glucagon Receptor Agonist" mean?
Survodutide activates two receptors: GLP-1 (which controls appetite and blood sugar) and glucagon (which increases energy expenditure). This is different from tirzepatide which activates GLP-1 and GIP instead.
Explained Simply
Your body has a "fullness" button (GLP-1) and a "burn more energy" button (glucagon). Survodutide presses both of these buttons at once, helping you eat less AND burn more energy.
How It Works
Survodutide combines GLP-1 receptor activation (reducing appetite and improving glucose handling) with glucagon receptor activation (increasing hepatic glucose output, lipolysis, and thermogenesis). The glucagon component may enhance weight loss beyond GLP-1 alone.
Research by Sex
Effects in Men
- •Phase 2 trials show robust weight loss in male subjects
- •Research indicates improvements in liver fat content
- •Metabolic rate increases observed in study populations
Effects in Women
- •Clinical data shows comparable efficacy in female participants
- •Liver fat reduction observed across both sexes
- •Weight loss outcomes similar to male participants
Key Terms Explained
Glucagon receptor
A receptor that when activated increases blood sugar and energy expenditure
NASH/MASH
Non-alcoholic/Metabolic steatohepatitis, a liver disease caused by fat accumulation
Research Areas
- •MASH/NASH (liver disease) treatment
- •Weight management via glucagon activation
- •Hepatic lipid metabolism
- •Energy expenditure enhancement
Published Studies
Laboratory Protocols
Storage
Store lyophilized peptide at -20°C.
Reconstitution
Reconstitute with bacteriostatic water or provided diluent.
Quick Facts
Category
Dual GLP-1/Glucagon Receptor Agonist
Molecular Weight
~4200 g/mol
Half-Life
~7 days
Amino Acid Sequence
Modified GLP-1/Glucagon dual agonist
Disclaimer: This information is provided for educational purposes only. These products are intended for laboratory research use only. Not for human consumption.